Psikiyatride Sık Kullanılan İlaçlar ve Sık Görülen İlaç Etkileşimleri
Özet
Ruhsal rahatsızlıkların tedavisinde kullanılan antidepresanlar, duygudurum dengeleyiciler, psikostimülanlar, benzodiazepinler ve antipsikotikler gibi temel psikofarmakolojik ajanlar ile bunların yan etkileri ve ilaç etkileşimleri psikiyatrik sağaltımda kritik bir öneme sahiptir. Antidepresanlar geniş bir yelpazede tercih edilirken; trisiklik antidepresanlar (TCA), selektif serotonin gerialım inhibitörleri (SGİ) ve serotonin noradrenalin gerialım inhibitörleri (SNGİ) gibi farklı grupların kendilerine has yan etki profilleri ve sitokrom P450 enzimi üzerinden farmakokinetik etkileşim riskleri mevcuttur. Bipolar bozuklukta kullanılan lityum, valproat ve karbamazepin gibi duygudurum dengeleyicilerin ise terapötik aralıklarının dar olması nedeniyle serum düzeyleri ve organ fonksiyonları düzenli takip edilmelidir; nitekim lityum toksisitesi veya serotonerjik ajanların kombinasyonuyla tetiklenen serotonin sendromu ölümcül sonuçlar doğurabilir. GABA nörotransmisyonunu güçlendiren benzodiazepinler kısa süreli anksiyolitik ve sedatif etkiler sunarken, uzun süreli kullanımda bağımlılık ve bilişsel bozulma riski taşır. Antipsikotikler ise şizofreni ve manik epizodlar gibi psikotik belirtilerin sağaltımında birinci ve ikinci kuşak olarak sınıflandırılır; ikinci kuşak ajanlar daha az ekstrapiramidal yan etki gösterse de metabolik profili olumsuz etkileyebilir ve tüm antipsikotikler potansiyel olarak ölümcül nöroleptik malign sendrom (NMS) riskini barındırır.
Psychopharmacological agents such as antidepressants, mood stabilizers, psychostimulants, benzodiazepines, and antipsychotics used in the treatment of mental disorders, along with their side effects and drug interactions, hold a critical role in psychiatric management. While antidepressants are preferred across a wide spectrum, different groups like tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) possess unique side effect profiles and pharmacokinetic interaction risks via cytochrome P450 enzymes. Mood stabilizers used in bipolar disorder, including lithium, valproate, and carbamazepine, require regular monitoring of serum levels and organ functions due to their narrow therapeutic windows; indeed, lithium toxicity or serotonin syndrome triggered by the combination of serotonergic agents can lead to fatal outcomes. Benzodiazepines, which enhance GABA neurotransmission, offer short-term anxiolytic and sedative effects but carry risks of dependence and cognitive impairment in long-term use. Antipsychotics are classified into first and second generations for the management of psychotic symptoms in conditions such as schizophrenia and manic episodes; although second-generation agents exhibit fewer extrapyramidal side effects, they can negatively impact the metabolic profile, and all antipsychotics carry the risk of the potentially fatal neuroleptic malignant syndrome (NMS).
Referanslar
Skånland SS, Cieślar-Pobuda A. Off-label uses of drugs for depression. European Journal of Pharmacology. 2019;865:172732.
Carvalho AF, Sharma MS, Brunoni AR, et al. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom. 2016;85(5):270-288.
Mariappan P, Ballantyne Z, N'Dow JM, et al. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst Rev. 2005(3):Cd004742.
Fava GA, Benasi G, Lucente M, et al. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychotherapy and Psychosomatics. 2018;87(4):195-203.
Keks NA, Hope J, Keogh S, et al. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant. Australas Psychiatry. 2018;26(5):537-540.
Khdour MR. Treatment of diabetic peripheral neuropathy: a review. Journal of Pharmacy and Pharmacology. 2020;72(7):863-872.
Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry: John Wiley & Sons; 2021.
Sub Laban T, Saadabadi A. Monoamine Oxidase Inhibitors (MAOI). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
Harrison P, Cowen P, Burns T, et al. Shorter Oxford textbook of psychiatry: Oxford university press; 2017.
Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020;212(7):329-334.
Howes S, Hartmann-Boyce J, Livingstone-Banks J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020;4(4):Cd000031.
Verbeeck W, Bekkering GE, Van den Noortgate W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017;10(10):Cd009504.
Öztürk MO, Uluşahin A. Ruh sağlığı ve bozuklukları: Nobel Tıp Kitabevleri; 2014.
Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Bmj. 2010;340:c693.
Francescangeli J, Karamchandani K, Powell M, et al. The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci. 2019;20(9):2288.
Wang RZ, Vashistha V, Kaur S, et al. Serotonin syndrome: Preventing, recognizing, and treating it. Cleve Clin J Med. 2016;83(11):810-817.
Won E, Kim YK. An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms. Int J Mol Sci. 2017;18(12).
Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cellular and Molecular Life Sciences. 2007;64(16):2090-2103.
Sadock B, Sadock V, Ruiz P. Kaplan and Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry 11 ed: Wolters Kluwer/Lippincott Williams & Wilkins; 2015.
Andrade C. Valproate in Pregnancy: Recent Research and Regulatory Responses. J Clin Psychiatry. 2018;79(3).
Naguy A, Al-Enezi N. Lamotrigine Uses in Psychiatric Practice. American Journal of Therapeutics. 2019;26(1).
Finley PR. Drug Interactions with Lithium: An Update. Clinical Pharmacokinetics. 2016;55(8):925-941.
Aydemir Ö, Uluşahin A, Akdeniz F. İki uçlu bozukluk sağaltım kılavuzu. 2. baskı. Ankara: TPD Yayınları. 2010.
Dunne FJ. Lithium toxicity: the importance of clinical signs. Br J Hosp Med (Lond). 2010;71(4):206-210.
Fay TB, Alpert MA. Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder Part 2: Impact on Cardiovascular Events and Recommendations for Evaluation and Monitoring. Cardiology in Review. 2019;27(4).
Fluyau D, Revadigar N, Manobianco BE. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Therapeutic Advances in Psychopharmacology. 2018;8(5):147-168.
Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. Archives of Clinical Neuropsychology. 2017;33(7):901-911.
Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatrica Scandinavica. 1998;98(s393):95-101.
Rudisill TM, Zhu M, Kelley GA, et al. Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review. Accident Analysis & Prevention. 2016;96:255-270.
Gandotra K, Chen P, Konicki PE, et al. Clonazepam-Related Paradoxical Behavioral Disinhibition: An Uncommon But Grave Adverse Effect. Journal of Clinical Psychopharmacology. 2019;39(3):281-282.
Esen-Danacı A, Böke Ö, Saka M, et al. Şizofreni ve diğer psikotik bozukluklar. Ankara: Türkiye Psikiyatri Derneği; 2018.
Citrome L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Review of Neurotherapeutics. 2017;17(10):1029-1043.
Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatric Clinics of North America. 2007;30(3):437-452.
Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS spectrums. 2014;19(1):3-5.
Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet. 2009;373(9657):31-41.
Velamoor R. Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management. Asian Journal of Psychiatry. 2017;29:106-109.
Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. The primary care companion for CNS disorders. 2018;20(1):27030.
Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. American Journal of Psychiatry. 1998;155(8):1113-1116.
van Rensburg R, Decloedt EH. An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome. Psychopharmacol Bull. 2019;49(1):84-91.
